Pioglitazone for Heroin and for Nicotine Dependence

• Status: Terminated
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of the proposed research is to improve the effectiveness of treatments for opioid and for nicotine dependence by testing a novel pharmacological strategy. Specifically, pioglitazone, a peroxisome proliferator-activated gamma receptor (PPARγ) agonist, will be used as an adjunct to agonist-based treatment.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: New York State Psychiatric Institute
• Collaborators: National Institute on Drug Abuse (NIDA); Omeros Corporation
• Treatments: Heroin; Nicotine; Pioglitazone

Criteria

Inclusion Criteria:

• 21-55 years of age

• Physically healthy

• Able to perform study procedures

Exclusion Criteria:

• Pregnancy

• Physical dependence on any other drugs besides caffeine, heroin and nicotine